What's all the hullabaloos about Aduhelm, the first new Alzheimer's drug approval since 2003? This month's MedEvidence guest, Dr. Steven Toenjes, MD, a board-certified neurologist, former staff neurologist in the U.S. Navy and an award-winning director of neurology residents at the Uniformed Services University of Health Sciences and decorated Navy veteran joins Dr. Michael Koren and Michelle McCormick to discuss the first new Alzheimer's drug approval since 2003 and the controversy over FDA's approval of Biogen's Aducanumab (Aduhelm).
If you enjoyed this episode, you will loves these:
Updated information on Medicare's decision to cover Alzheimer's drugs
Schedule a Free Memory Screening
Original Air Date: March 11, 2022
Be a part of advancing science by participating in clinical research
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Sponsored by ENCORE Research Group
Thank you for listening!